Skip to content
10-K

Annual Report

NKGen Biotech, Inc.

0001845459-25-000004

← back to feed
Filed
Oct 8, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Oct 7, 2025 124.38M sh
Shares Diluted FY 2024 · Dec 31, 2024 28.83M sh
Shares Diluted FY 2024 · Dec 31, 2023 15.43M sh
Operating Cash Flow FY 2024 · Dec 31, 2024 −$20.88M
Operating Cash Flow FY 2024 · Dec 31, 2023 −$21.95M
Cash And Equivalents FY 2024 · Dec 31, 2024 $106K
Cash And Equivalents FY 2024 · Dec 31, 2023 $26K
Stockholders Equity FY 2024 · Dec 31, 2024 −$69.91M
Stockholders Equity FY 2024 · Dec 31, 2023 −$58.69M
Stockholders Equity restated FY 2024 · Dec 31, 2022 $1.56M
Current Liabilities FY 2024 · Dec 31, 2024 $57.97M
Current Liabilities FY 2024 · Dec 31, 2023 $39.45M
Total Liabilities FY 2024 · Dec 31, 2024 $86.14M
Total Liabilities FY 2024 · Dec 31, 2023 $75.17M
Current Assets FY 2024 · Dec 31, 2024 $2.46M
Current Assets FY 2024 · Dec 31, 2023 $1.93M
Total Assets FY 2024 · Dec 31, 2024 $16.23M
Total Assets FY 2024 · Dec 31, 2023 $16.48M
Eps Diluted FY 2024 · Dec 31, 2024 −$1.54
Eps Diluted FY 2024 · Dec 31, 2023 −$5.38
Eps Basic FY 2024 · Dec 31, 2024 −$1.54
Eps Basic FY 2024 · Dec 31, 2023 −$5.38
Rd Expense FY 2024 · Dec 31, 2024 $10.66M
Rd Expense FY 2024 · Dec 31, 2023 $15.67M
Net Income FY 2024 · Dec 31, 2024 −$44.29M
Net Income FY 2024 · Dec 31, 2023 −$82.95M
Operating Income FY 2024 · Dec 31, 2024 −$26.97M
Operating Income FY 2024 · Dec 31, 2023 −$29.75M